The European regulatory experience
- 20 September 2002
- journal article
- Published by Wiley in Statistics in Medicine
- Vol. 21 (19), 2931-2938
- https://doi.org/10.1002/sim.1297
Abstract
This paper discusses four methodological topics that have been a regular source of difficulty and debate in European regulatory work. (i) The increasing use of non‐inferiority trials in the development of medicinal products has highlighted several problems. These relate first to the choice of the non‐inferiority margin and secondly to the circumstances under which a non‐inferiority design is or is not appropriate. (ii) The use of meta‐analysis in regulatory applications is still controversial and acceptable uses need to be defined. (iii) Analysis of responders provides a useful insight into the size of treatment benefits but can be misleading, especially when it is impossible to be certain whether or not an individual patient has truly responded to treatment. (iv) The extent of the monitoring of clinical trial procedures and data still distinguishes industry‐sponsored trials from other trials: it is not clear that it should. These questions are all equally important for those involved in clinical trial work outside the arena of pharmaceutical development. Copyright © 2002 John Wiley & Sons, Ltd.Keywords
This publication has 6 references indexed in Scilit:
- The Procedure of New Drug Application and the Philosophy of Critical Rationalism or The Limits of Quality Assurance with Good Clinical PracticeControlled Clinical Trials, 1999
- Statistical principles for clinical trials (ICH E9): an introductory note on an international guidelineStatistics in Medicine, 1999
- One Large, Well-Designed, Multicenter Study as an Alternative to the Usual Fda ParadigmDrug Information Journal, 1999
- Trials: the next 50 yearsBMJ, 1998
- Trials to assess equivalence: the importance of rigorous methodsBMJ, 1996
- Statistical issues in the regulation of medicinesStatistics in Medicine, 1995